A Phase 3 interventional study of Denosumab and Placebo in Evaluate the Safety and Efficacy of Denosumab in Pediatric Subjects With and Glucocorticoid-induced Osteoporosis, sponsored by Amgen. Completed at 38 sites in 13 countries. Open to participants aged 5 Years to 17 Years. Per ClinicalTrials.gov, last updated 2024-07-19.
Sponsored by Amgen · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 64 studies testing denosumab in Osteoporosis — 8 open to participants now, 11 under way, 2 of them phase 3. Denosumab · Osteoporosis.
Among the 64 studies testing denosumab in Osteoporosis, this one is the 51st largest by enrollment, is one of 5 that started in 2018, is one of 24 in phase 3, and was the 36th registered.
1,602 studies on the registry are indexed under Osteoporosis; 210 are open to participants now.
Browse Osteoporosis studies →8 of the 64 studies testing denosumab in Osteoporosis are open now, in 8 countries. Recruiting first, the newest first:
National Taiwan University Hospital · Sites in Taiwan
Ages 50–80 · Women only
Qilu Pharmaceutical Co., Ltd. · Sites in China
Ages 50–85 · Women only
Aarhus University Hospital · Sites in Denmark
Ages 40+ · Women only
Chrissy Kistler · Sites in United States
Ages 65+
Wuhan Union Hospital, China · Sites in China
Ages 40+
By country, each count listing its studies:
Denosumab: first FDA approval 2010 (PROLIA), first EMA approval 2010. What it is approved for, and how studies give it, is on its page →
Of the 133 Osteoporosis studies recruiting now, 77 (58%) set no upper age limit and 20 (15%) stop at 75 or younger; 9 take children under 18; 36 take healthy volunteers.
This study: 5 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
64 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 16 · Phase 3 25 · Phase 4 19
First in 2002; this study’s year is marked. 5 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 24 is below the median of 88 across 1,084 interventional studies indexed under Osteoporosis.
Median enrollment 90 across the 64 interventional studies. Of the 45 that completed or were terminated, 32 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
30 of 64 have an industry lead sponsor. The 10 most frequent:
Amgen is the lead sponsor of 1,047 studies on the registry; 51 are open to participants now.
Of its 246 completed or terminated interventional studies of FDA-regulated products, 166 (67%) have results posted.
34 studies in Osteoporosis by Amgen: none open now, 2 under way, none of them phase 3. Of 32 finished, 31 (97%) have results posted.
Among the 34 studies in Osteoporosis by Amgen, this one is the 28th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2018, is one of 18 in phase 3, and was the 30th registered.
Amgen’s Osteoporosis studies by the year they started, since 2002.
6 of the studies testing denosumab in Osteoporosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07062978Phase 3Qilu Pharmaceutical Co., Ltd.A Comparative Study to Valuating the Efficacy and Safety of QL1206 and Prolia® | 2027-01 |
| NCT06332014AmgenEvaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China | 2027-01-23 |
| NCT04608630Australian and New Zealand Intensive Care Research CentreBone Loss Prevention With Zoledronic Acid or Denosumab in Critically Ill Adults | 2027-02-28 |
| NCT04800367Columbia UniversityRomosozumab/Denosumab Study for Premenopausal IOP | 2027-03 |
| NCT07271771Aarhus University HospitalThe Effect of Denosumab on Muscle and Strength and Insulin Sensitivity | 2027-03-01 |
Add all 6 to your calendar (.ics) → With an account.
Among the 64 studies testing denosumab in Osteoporosis, from their registry updates:
Among Amgen’s 34 in Osteoporosis:
This tab as a report to print or save as PDF → With an account.
To evaluate the effect of denosumab on lumbar spine bone mineral density (BMD) Z-score as assessed by dual-energy X-ray absorptiometry (DXA) at 12 months in children 5 to 17 year of age with Glucocorticoid (GC)-induced osteoporosis (GiOP).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Evidence of at least 1 vertebral compression fracture of Genant grade 1 or higher, as assessed by the central imaging vendor on lateral spine X-rays performed at screening or within 2 months prior to screening; OR, in the absence of vertebral compression fractures, presence of both fracture history (ie, ≥ 2 long-bone fractures by age 10 years or ≥ 3 long-bone fractures at any age up to 17 years) and lumbar spine BMD Z-score ≤ -2.0, as assessed by the central imaging vendor.
Exclusion criteria will include the following:
History of
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SC Q6M placebo
Other: Placebo
1 mg/kg BW (up to a maximum of 60 mg) SC Q6M
Drug: Denosumab
1mg/kg BW (up to a maximum of 60 mg) SC Q6M
SC Q6M placebo
Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months
Lumbar spine BMD was assessed by DXA and analyzed by analysis of covariance (ANCOVA) including treatment (denosumab vs placebo), baseline age, and baseline BMD z-score. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.
Time frame: Baseline and 12 Months
Change From Baseline in Lumbar Spine BMD Z-score as Assessed by DXA at 6, 18, 24, and 36 Months
Lumbar spine BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.
Time frame: Baseline and 6, 18, 24, and 36 Months
Change From Baseline in Proximal Femur BMD Z-score as Assessed by DXA at 6, 12, 18, 24, and 36 Months
Proximal femur (total hip and femoral neck) BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify proximal femur BMD improvement.
Time frame: Baseline and 6, 12, 18, 24, and 36 Months
Number of Participants With X-ray Confirmed Long-bone Fractures and/or Vertebral Fractures at 12, 24, and 36 Months
Number of participants who have at least one long bone fracture or vertebral fracture, and number of participants who have more than one long bone fracture or vertebral fracture.
Time frame: Month 12, 24, and 36
Number of Participants With Improving Vertebral Fractures at 12, 24, and 36 Months
Number of participants with improving vertebral fractures. An improving fracture is defined as one showing signs of healing/repair from baseline as assessed by X-ray.
Time frame: Month 12, 24, and 36
Number of Participants With New and Worsening Vertebral and Non-vertebral Fractures at 12, 24, and 36 Months
Number of participants who have at least one vertebral fracture or non-vertebral fracture, and number of participants who have more than one vertebral fracture or non-vertebral fracture.
Time frame: Month 12, 24, and 36
Change From Baseline in Child Health Questionnaire-Parent Form-50 (CHQ-PF-50) Physical Summary Score at 12, 24, and 36 Months
The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The physical summary score ranges from 0-100 with higher scores indicating better physical health.
Time frame: Baseline and month 12, 24, and 36
Change From Baseline in CHQ-PF-50 Psychological Summary Score at 12, 24, and 36 Months
The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The psychological summary score ranges from 0-100 with higher scores indicating better psychological health.
Time frame: Baseline and Month 12, 24, and 36
Change From Baseline in Childhood Health Assessment Questionnaire (CHAQ) Disability Index Score at 12, 24, and 36 Months
The CHAQ was developed to measure the physical functioning in children 6 months to 18 years of age. It consists of 54 questions related to the child's ability to perform various activities of daily living. Depending on the question asked, each question is scored either 0 to 3 based on the level of difficulty experienced by the child or 0-1 based on whether the child required assistance from another person or used an aid or other device. All CHAQ questions were scored and converted to a total index score ranging from 0-3, where higher scores indicate greater disability.
Time frame: Baseline and Month 12, 24, and 36
Change From Baseline in Wong-Baker FACES Pain Rating Scale (WBFPRS) at 12, 24, and 36 Months
The WBFPRS is a horizontal pain scale for children 3-18 years which consists of 6 faces that range from a smiling "no hurt" face with a score of 0 to a crying "hurts worst" face with a score of 10.
Time frame: Baseline and Month 12, 24, and 36
Change From Baseline in Growth Velocity Z-score (Height) at 12, 24, and 36 Months
Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and body mass index (BMI). Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.
Time frame: Baseline and Month 12, 24, and 36
Change From Baseline in Growth Velocity Z-score (Weight) at 12, 24, and 36 Months
Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.
Time frame: Baseline and Month 12, 24, and 36
Change From Baseline in Growth Velocity Z-score (BMI) at 12, 24, and 36 Months
Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.
Time frame: Baseline and Month 12, 24, and 36
Mean Serum Concentration of Denosumab
Time frame: Day 1, Day 10, Day 30, Month 3, Month 6, Month 12, and Month 18
This study was conducted at 12 center(s) in Australia, Canada, Columbia, India, Peru, Russia, Turkey, Ukraine, and the United States between May 2018 and December 2023.
| Milestone | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Started | 16 | 8 |
| Completed | 15 | 8 |
| Not completed | 1 | 0 |
| Withdrew: Lost to follow-up | 1 | 0 |
Lumbar spine BMD was assessed by DXA and analyzed by analysis of covariance (ANCOVA) including treatment (denosumab vs placebo), baseline age, and baseline BMD z-score. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.
| Z-score | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Change From Baseline in Lumbar Spine BMD Z-score as Assessed by Dual-energy X-ray Absorptiometry (DXA) at 12 Months | 0.23 (-0.054 to 0.506) | 0.11 (-0.304 to 0.532) |
Lumbar spine BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify lumbar spine BMD improvement.
| Z-score | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 6 | 0.28 (0.095 to 0.468) | 0.11 (-0.176 to 0.391) |
| Month 18 | 0.32 (-0.034 to 0.679) | 0.30 (-0.206 to 0.800) |
| Month 24 | 0.37 (-0.017 to 0.755) | 0.26 (-0.285 to 0.801) |
| Month 36 | -0.23 (-0.833 to 0.372) | 0.57 (-0.268 to 1.416) |
Proximal femur (total hip and femoral neck) BMD was assessed by DXA and analyzed by repeated measures analysis with randomization group, visit, baseline age, and baseline BMD z-score as fixed effects. Treatment-by-visit was included as an interaction term. DXA results were converted to z-scores, indicating number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify proximal femur BMD improvement.
| Z-score | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 6 (Total Hip) | 0.22 (-0.103 to 0.552) | 0.64 (0.104 to 1.171) |
| Month 12 (Total Hip) | 0.24 (-0.079 to 0.554) | 0.30 (-0.168 to 0.759) |
| Month 18 (Total Hip) | 0.48 (0.015 to 0.937) | 0.75 (0.061 to 1.434) |
| Month 24 (Total Hip) | 0.52 (0.000 to 1.033) | 0.69 (-0.062 to 1.447) |
| Month 36 (Total Hip) | 0.64 (-0.149 to 1.436) | 0.73 (-0.384 to 1.850) |
| Month 6 (Femoral Neck) | 0.42 (0.000 to 0.849) | 0.60 (-0.037 to 1.241) |
| Month 12 (Femoral Neck) | 0.53 (0.029 to 1.030) | 0.43 (-0.294 to 1.161) |
| Month 18 (Femoral Neck) | 0.85 (0.261 to 1.446) | 0.48 (-0.387 to 1.350) |
| Month 24 (Femoral Neck) | 0.75 (0.000 to 1.495) | 0.64 (-0.449 to 1.724) |
| Month 36 (Femoral Neck) | 1.00 (-0.008 to 2.012) | 0.63 (-0.798 to 2.050) |
Number of participants who have at least one long bone fracture or vertebral fracture, and number of participants who have more than one long bone fracture or vertebral fracture.
| Participants | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 (at least 1 fracture) | 2 | 2 |
| Month 24 (at least 1 fracture) | 3 | 3 |
| Month 36 (at least 1 fracture) | 3 | 3 |
| Month 12 (more than 1 fracture) | 2 | 1 |
| Month 24 (more than 1 fracture) | 2 | 0 |
| Month 36 (more than 1 fracture) | 3 | 1 |
Number of participants with improving vertebral fractures. An improving fracture is defined as one showing signs of healing/repair from baseline as assessed by X-ray.
| Participants | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | 3 | 1 |
| Month 24 | 2 | 1 |
| Month 36 | 1 | 2 |
Number of participants who have at least one vertebral fracture or non-vertebral fracture, and number of participants who have more than one vertebral fracture or non-vertebral fracture.
| Participants | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 (at least 1 fracture) | 2 | 2 |
| Month 24 (at least 1 fracture) | 3 | 3 |
| Month 36 (at least 1 fracture) | 3 | 3 |
| Month 12 (more than 1 fracture) | 2 | 1 |
| Month 24 (more than 1 fracture) | 2 | 0 |
| Month 36 (more than 1 fracture) | 3 | 1 |
The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The physical summary score ranges from 0-100 with higher scores indicating better physical health.
| Scores on a scale | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | 5.26 ± 8.88 | 8.53 ± 16.39 |
| Month 24 | 5.62 ± 7.39 | 19.88 ± 15.20 |
| Month 36 | 4.48 ± 8.89 | 14.18 ± 8.14 |
The CHQ-PF-50 is a 50-item questionnaire to be completed by the parents or guardians of children between 5 and 18 years of age. The psychological summary score ranges from 0-100 with higher scores indicating better psychological health.
| Scores on a scale | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | 0.71 ± 9.15 | -0.10 ± 12.52 |
| Month 24 | 2.58 ± 12.58 | 1.90 ± 9.76 |
| Month 36 | 5.20 ± 10.09 | 2.00 ± 9.33 |
The CHAQ was developed to measure the physical functioning in children 6 months to 18 years of age. It consists of 54 questions related to the child's ability to perform various activities of daily living. Depending on the question asked, each question is scored either 0 to 3 based on the level of difficulty experienced by the child or 0-1 based on whether the child required assistance from another person or used an aid or other device. All CHAQ questions were scored and converted to a total index score ranging from 0-3, where higher scores indicate greater disability.
| Scores on a scale | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | -0.06 ± 0.32 | -0.29 ± 0.44 |
| Month 24 | -0.09 ± 0.33 | -0.30 ± 0.49 |
| Month 36 | -0.12 ± 0.45 | -0.43 ± 0.45 |
The WBFPRS is a horizontal pain scale for children 3-18 years which consists of 6 faces that range from a smiling "no hurt" face with a score of 0 to a crying "hurts worst" face with a score of 10.
| Scores on a scale | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | -0.7 ± 3.3 | -0.3 ± 3.9 |
| Month 24 | -0.6 ± 2.9 | -2.4 ± 0.9 |
| Month 36 | -2.5 ± 1.8 | 0.0 ± 1.4 |
Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and body mass index (BMI). Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.
| Z-score | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | -0.18 ± 0.46 | -0.07 ± 0.84 |
| Month 24 | -0.11 ± 0.90 | -0.27 ± 1.17 |
| Month 36 | -0.33 ± 0.84 | 0.01 ± 1.35 |
Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.
| Z-score | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | -0.12 ± 0.44 | -0.10 ± 0.49 |
| Month 24 | -0.22 ± 0.73 | -0.68 ± 0.62 |
| Month 36 | -0.32 ± 0.90 | -0.44 ± 0.60 |
Growth velocity was determined by calculating age-adjusted z-scores for height, weight, and BMI. Z-scores represent the number of standard deviations from the reference population's mean, with 0 denoting the mean. Positive changes from baseline signify increased growth velocity.
| Z-score | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Month 12 | -0.03 ± 0.53 | -0.14 ± 0.54 |
| Month 24 | -0.12 ± 0.80 | -0.75 ± 1.02 |
| Month 36 | -0.12 ± 0.84 | -0.72 ± 0.97 |
| ng/mL | Denosumab/Denosumab | Placebo/Denosumab |
|---|---|---|
| Day 1 | 0.00 ± 0.00 | — |
| Day 10 | 10300 ± 7900 | — |
| Day 30 | 6830 ± 4770 | — |
| Month 3 | 1100 ± 935 | — |
| Month 6 | 141 ± 338 | — |
| Month 12 | 157 ± 349 | 0.00 ± 0.00 |
| Month 18 | 49 ± 154 | 7.61 ± 21.5 |
Collected over From date of enrollment through last dose, up to 36 months.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Baseline-Month 12: Placebo | 0/8 (0%) | 1/8 (12.5%) | 5/8 (62.5%) |
| Baseline-Month 12: Denosumab | 0/16 (0%) | 3/16 (18.8%) | 11/16 (68.8%) |
| Baseline-Month 24: Placebo/Denosumab | 0/8 (0%) | 1/8 (12.5%) | 5/8 (62.5%) |
| Baseline-Month 24: Denosumab/Denosumab | 0/16 (0%) | 3/16 (18.8%) | 12/16 (75%) |
| Baseline-Month 36: Placebo/Denosumab | 0/8 (0%) | 2/8 (25%) | 5/8 (62.5%) |
| Baseline-Month 36: Denosumab/Denosumab | 0/16 (0%) | 4/16 (25%) | 13/16 (81.3%) |
| Event | Baseline-Month 12: Placebo | Baseline-Month 12: Denosumab | Baseline-Month 24: Placebo/Denosumab | Baseline-Month 24: Denosumab/Denosumab | Baseline-Month 36: Placebo/Denosumab | Baseline-Month 36: Denosumab/Denosumab |
|---|---|---|---|---|---|---|
| CardiomyopathyCardiac disorders | 1/8 | 0/16 | 1/8 | 0/16 | 1/8 | 0/16 |
| UreterolithiasisRenal and urinary disorders | 0/8 | 0/16 | 0/8 | 0/16 | 1/8 | 0/16 |
| Autoimmune hepatitisHepatobiliary disorders | 0/8 | 1/16 | 0/8 | 1/16 | 0/8 | 1/16 |
| Urinary tract infectionInfections and infestations | 0/8 | 0/16 | 0/8 | 0/16 | 0/8 | 1/16 |
| Brain contusionInjury, poisoning and procedural complications | 0/8 | 1/16 | 0/8 | 1/16 | 0/8 | 1/16 |
| Femur fractureInjury, poisoning and procedural complications | 0/8 | 1/16 | 0/8 | 1/16 | 0/8 | 1/16 |
| Tibia fractureInjury, poisoning and procedural complications | 0/8 | 1/16 | 0/8 | 1/16 | 0/8 | 1/16 |
| Uterine haemorrhageReproductive system and breast disorders | 0/8 | 1/16 | 0/8 | 1/16 | 0/8 | 1/16 |
| Event | Baseline-Month 12: Placebo | Baseline-Month 12: Denosumab | Baseline-Month 24: Placebo/Denosumab | Baseline-Month 24: Denosumab/Denosumab | Baseline-Month 36: Placebo/Denosumab | Baseline-Month 36: Denosumab/Denosumab |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 1/8 | 0/16 | 1/8 | 0/16 | 1/8 | 3/16 |
| HeadacheNervous system disorders | 1/8 | 2/16 | 1/8 | 2/16 | 1/8 | 3/16 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 2/16 | 0/8 | 2/16 | 0/8 | 2/16 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/8 | 0/16 | 1/8 | 0/16 | 1/8 | 0/16 |
| CardiomyopathyCardiac disorders | 0/8 | 0/16 | 0/8 | 0/16 | 1/8 | 0/16 |
| TachycardiaCardiac disorders | 0/8 | 1/16 | 0/8 | 2/16 | 0/8 | 2/16 |
| Intracranial lipomaCongenital, familial and genetic disorders | 0/8 | 0/16 | 0/8 | 0/16 | 1/8 | 0/16 |
| Delayed pubertyEndocrine disorders | 0/8 | 1/16 | 0/8 | 1/16 | 0/8 | 2/16 |
| AstigmatismEye disorders | 1/8 | 0/16 | 1/8 | 0/16 | 1/8 | 0/16 |
| Cataract subcapsularEye disorders | 1/8 | 0/16 | 1/8 | 0/16 | 1/8 | 0/16 |
Full Analysis Set (FAS): all participants enrolled into the study.
| Age, Continuous(Years) | Denosumab/Denosumab | Placebo/Denosumab | Total |
|---|---|---|---|
| Mean | 13.8 ± 2.3 | 12.8 ± 2.1 | 13.4 ± 2.2 |
| Sex: Female, Male(Participants) | Denosumab/Denosumab | Placebo/Denosumab | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 10 | 4 | 14 |
| Ethnicity (NIH/OMB)(Participants) | Denosumab/Denosumab | Placebo/Denosumab | Total |
|---|---|---|---|
| Hispanic or Latino | 1 | 3 | 4 |
| Not Hispanic or Latino | 15 | 5 | 20 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Denosumab/Denosumab | Placebo/Denosumab | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 3 | 0 | 3 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 |
| White | 13 | 5 | 18 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 3 | 3 |
| Bone Mineral Density (BMD) Z-score at Baseline(Z-score) | Denosumab/Denosumab | Placebo/Denosumab | Total |
|---|---|---|---|
| Lumbar Spine | -1.95 ± 1.03 | -3.60 ± 1.77 | -2.50 ± 1.51 |
| Total Hip | -3.14 ± 1.70 | -4.56 ± 2.08 | -3.58 ± 1.90 |
| Femoral Neck | -3.35 ± 1.91 | -4.78 ± 2.80 | -3.79 ± 2.25 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.
Access criteria: Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors. If not approved, a Data Sharing Independent Review Panel will arbitrate and make the final decision. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the link below.
Data sharing details ↗ · www.amgen.com
Ran from May 2018 to primary completion in Dec 2021, 43 months.
Results were first posted in Jul 2024, 2 years 7 months after primary completion.
Of 35 industry-sponsored phase 3 interventional studies under Osteoporosis, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 46. This study's 43 months is above that.
Counting every sponsor, half of 45 studies reached it within 37 months; a quarter within 21 and three quarters within 57.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Denosumab